Is KPV legal? US, UK and Australia status (2026)

The short answer

KPV is not an approved medicine in the US, UK or Australia and is not a controlled drug in the US or UK. In the US it moved closer to pharmacy compounding after a July 2026 advisory vote, but it was not yet on the 503A bulks list in October 2026, and in Australia unapproved peptide products like KPV are covered by the TGA's 2026 enforcement drive.

KPV is the tripeptide lysine-proline-valine, the C-terminal fragment of alpha-melanocyte-stimulating hormone (alpha-MSH). It has been studied mainly in cell culture and rodent models of intestinal inflammation. That research does not change its legal status.

KPV status at a glance (October 2026)

United States

The FDA placed KPV in 503A Category 2 on 29 September 2023. Its stated reason was that it had not identified any human exposure data on drug products containing KPV by any route, and so lacked important safety information. On 22 April 2026 KPV was moved off Category 2 after the nominators withdrew their nominations.

At the 23 July 2026 Pharmacy Compounding Advisory Committee meeting, KPV free base and acetate were each recommended for the 503A bulks list by 8 votes to 6 with one abstention. The FDA's staff had recommended against. The vote is advisory, and KPV cannot be lawfully compounded under 503A until the FDA completes rulemaking. KPV is not a controlled substance.

United Kingdom

KPV is not controlled under the Misuse of Drugs Act 1971 and has no UK marketing authorisation. As with other peptides, the Human Medicines Regulations 2012 apply where KPV is presented as treating a condition or used to modify physiological function, and the MHRA said in April 2026 that clinics making medicinal claims about peptide injections would have those products treated as medicines.

Australia

We could not find a named Poisons Standard entry for KPV, so it is not scheduled by name in the way BPC-157 and TB-500 are. That does not make it unregulated. Therapeutic goods must be entered on the Australian Register of Therapeutic Goods before they can be lawfully imported, advertised or supplied unless an exemption applies, and the TGA has said it is unlawful to import, advertise, manufacture or supply unapproved peptide products in Australia.

The TGA's 2026 enforcement has focused on named peptides, but its compliance priority covers unapproved peptide products generally. Anyone in Australia should treat KPV supplied for human use as an unapproved therapeutic good.

Sport

KPV is not named on the 2026 WADA Prohibited List. S0 prohibits any pharmacological substance that is not addressed elsewhere on the List and has no current approval by any government health authority for human therapeutic use. USADA notes that not every prohibited peptide is listed by name in Global DRO, and its advisory on the 2027 List says peptides in general are now named in S0. Athletes should assume an unapproved peptide such as KPV is prohibited unless their anti-doping agency confirms otherwise.

Common misreadings of KPV's status

Three claims circulate online that the record does not support. First, that the FDA approved KPV in July 2026: it did not; an advisory committee made a non-binding recommendation about pharmacy compounding, and no KPV drug product has been approved. Second, that KPV is legal everywhere because it is not scheduled: in the UK and Australia the question is whether it is being supplied or presented as a medicine, and an unapproved therapeutic good does not need a named schedule entry to be regulated. Third, that KPV is fine for athletes because WADA does not name it: S0 is written as a catch-all for unapproved substances.

What to watch next

The open question for KPV is the FDA's response to the July 2026 recommendation: a proposed rule adding it to the 503A bulks list, or an interim Category 1 placement, would be the next formal step, and each would be published by the FDA. In Australia, any move to schedule KPV by name would normally be preceded by a published TGA scheduling proposal. We log both in our peptide regulation tracker.

Where Celyfe fits

Celyfe supplies KPV only in the KLOW research pen, a pre-filled 3 ml cartridge containing GHK-Cu 75 mg, BPC-157 15 mg, TB-500 15 mg and KPV 15 mg. The KLOW certificate of analysis is being re-issued and will be listed in the Celyfe COA library when published.

Sources

Checked 8 October 2026:

• FDA: Certain bulk drug substances for use in compounding that may present significant safety risks (KPV entry dated 29 Sep 2023; current page as of 22 Apr 2026), fda.gov
• FDA: July 23-24, 2026 meeting of the Pharmacy Compounding Advisory Committee, fda.gov
• The FDA Law Blog: PCAC approves four bulk drug substances for the 503A list, 24 Jul 2026
• TGA media releases: compliance focus on unapproved peptide products (10 Jun 2026); TGA flexes its muscle against illegal peptides and steroids (Aug 2026); more than $126k in infringement notices (6 Oct 2026), tga.gov.au
• The Guardian: Medicines watchdog to investigate UK peptide clinics over health claims, 4 Apr 2026
• WADA: Prohibited List 2026 (S0), wada-ama.org
• USADA: What's new on the 2027 WADA Prohibited List, usada.org

Research use only

Celyfe supplies research peptides for laboratory and research use only. Nothing on this page is guidance on use in humans or animals. This is general information, not legal advice. Rules in all three countries changed several times in 2026, so check the regulator's current publications or speak to a qualified adviser before relying on anything here.